Dosing & Uses
Dosage Forms & Strengths
tablet
- 18.2mg
- 36.3mg
- 54.5mg
- 72.6mg
Major Depressive Disorder
Indicated for the treatment of major depressive disorder (MDD)
18.2 mg PO qDay
Based on clinical response and tolerability
- May increase to 36.3 mg qDay on Day 4
- Further titrate to 54.5 mg qDay after Day 7
- Then, 72.6 mg qDay after an additional week; maximum recommended daily dosage 72.6 mg qDay
Dosage Modifications
Coadministration of CYP3A4 Inhibitors
- Moderate CYP3A4 inhibitors: Reduce gepirone dose by 50%
- Strong CYP3A4 inhibitors: Contraindicated
Switching to or from a monoamine oxidase inhibitor (MAOI) antidepressant
- At least 14 days must elapse between discontinuation of an MAOI and initiating gepirone
- Allow at least 14 days after stopping gepirone before starting an MAOI antidepressant
Renal impairment
- CrCl ≥50 mL/min: No dosage adjustment necessary
- CrCl <50 mL/min: Start at 18.2 mg qDay; may increase to maximum recommended dosage of 36.3 mg qDay after Day 7 based on clinical response and tolerability
Hepatic impairment
- Mild (Child-Pugh A): No dosage adjustment necessary
- Moderate (Child-Pugh B): Start at 18.2 mg qDay; may increase to maximum recommended dosage of 36.3 mg qDay after Day 7 based on clinical response and tolerability
- Severe (Child-Pugh C): Contraindicated
Dosing Considerations
Screen for a personal or family history of bipolar disorder, mania, or hypomania before initiating treatment
Advise patients to inform healthcare provider if taking, or plan to take, any prescription or over-the-counter medications due to an increased risk for drug interactions with this medication
Electrolyte abnormalities and electrocardiogram (ECG)
- Correct electrolyte abnormalities before initiating for patients with electrolyte abnormalities, or who are receiving diuretics or glucocorticoids, or who have a history of hypokalemia or hypomagnesemia
- Monitor electrolytes during dose titration and periodically during treatment
- Perform an ECG before initiating, during dosage titration, and periodically during treatment
- Do not initiate if QTc is >450 msec at baseline
-
Monitor ECGs more frequently if used with:
- Drugs known to prolong the QT interval
- Patients who develop QTc ≥450 msec during treatment
- Patients with a significant risk of developing torsade de pointes
- Do not escalate dosage if QTcF is 450 msec
Safety and efficacy not established
Major Depressive Disorder
Indicated for the treatment of major depressive disorder (MDD)
18.2 mg PO qDay
Based on clinical response and tolerability, may increase dosage to maximum recommended dosage of 36.3 mg qDay after Day 7
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Contraindicated (0)
Serious - Use Alternative (1)
- olopatadine intranasal
gepirone and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
Monitor Closely (10)
- daridorexant
gepirone and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- diazepam intranasal
diazepam intranasal, gepirone. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.
- difelikefalin
difelikefalin and gepirone both increase sedation. Use Caution/Monitor.
- fenfluramine
fenfluramine, gepirone. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration with drugs that increase serotoninergic effects may increase the risk of serotonin syndrome.
- gabapentin
gabapentin, gepirone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- gabapentin enacarbil
gabapentin enacarbil, gepirone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- ganaxolone
gepirone and ganaxolone both increase sedation. Use Caution/Monitor.
- lasmiditan
lasmiditan, gepirone. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.
- pregabalin
pregabalin, gepirone. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- remimazolam
remimazolam, gepirone. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely. Coadministration may result in profound sedation, respiratory depression, coma, and/or death. Continuously monitor vital signs during sedation and recovery period if coadministered. Carefully titrate remimazolam dose if administered with opioid analgesics and/or sedative/hypnotics.
Minor (0)
Adverse Effects
>10%
Dizziness (49%)
Nausea (35%)
Headache (31%)
Feeling sleepy or tired (15%)
Insomnia (14%)
1-10%
Diarrhea (10%)
Upper respiratory tract infection (8%)
Dry mouth (8%)
Vomiting (7%)
Abdominal pain (7%)
Dyspepsia (6%)
Increased appetite (5%)
Constipation (4%)
Nasopharyngitis (4%)
Nasal congestion (4%)
Paresthesia (4%)
Hyperhidrosis (4%)
Palpitations (4%)
Weight increased (3%)
Agitation (3%)
Feeling jittery (3%)
Heart rate increased (2%)
Lethargy (2%)
Breast tenderness (<2%)
Confusional state (<2%)
Dyspnea(<2%)
Edema peripheral (<2%)
Energy increased (<2%)
Feeling abnormal (<2%)
Hypoesthesia (<2%)
Poor quality sleep (<2%)
Thinking abnormal (<2%)
Frequency not defined
Hypersensitivity reactions
Warnings
Black Box Warnings
Suicidal thoughts and behaviors
- Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adults in short-term studies
- Closely monitor all antidepressant-treated patients for clinical worsening and emergence of suicidal thoughts and behaviors
- Not approved for use in pediatric patients
Contraindications
Known hypersensitivity to gepirone or components
Prolonged QTc interval >450 msec at baseline
Congenital long QT syndrome
Concomitant use of strong CYP3A4 inhibitors
Severe hepatic impairment
Use with an MAOI or within 14 days of stopping treatment; do not use within 14 days of discontinuing an MAOI
Cautions
Antidepressant treatment can precipitate a manic, mixed, or hypomanic manic episode; risk appears to be increased in patients with bipolar disorder or who have risk factors for bipolar disorder, before initiating treatment, screen for history of bipolar disorder and the presence of risk factors for bipolar disorder (eg, family history of bipolar disorder, suicide, or depression)
Not approved for use in treating bipolar depression
Suicidal thoughts and behaviors in adolescents and young adults
- Incidence of suicidal thoughts and behaviors in antidepressant-treated patients aged ≤24 years was greater than in placebo-treated patients
- Risk of suicidal thoughts and behaviors varies among drugs, but there was an increased risk identified in young patients for most drugs studied
- Monitor for clinical worsening and emergence of suicidal thoughts and behaviors, especially during initial few months of drug therapy, and when dose is adjusted
- Counsel family members or caregivers of patients to monitor for changes in behavior and to alert healthcare provider
- Consider changing therapeutic regimen, including possibly discontinuing, in patients whose depression is persistently worse, or who are experiencing emergent suicidal thoughts or behaviors
QT prolongation
- May prolongs QTc interval
- Contraindicated in patients with congenital long QT syndrome
- Do not initiate if QTc is >450 msec at baseline
- Correct electrolyte abnormalities before initiating
- In patients with electrolyte abnormalities, who are receiving diuretics or glucocorticoids, or have a history of hypokalemia or hypomagnesemia, monitor electrolytes during dose titration and periodically during treatment
- Perform an ECG before initiation, during dosage titration, and periodically during treatment.
-
Monitor ECGs more frequently
- Coadministration with drugs known to prolong the QT interval
- Patients who develop QTc ≥450 msec during treatment;do not escalate dosage if QTcF is >450 msec
- Patients with a significant risk of developing torsade de pointes, including those with uncontrolled or significant cardiac disease, recent myocardial infarction, heart failure, unstable angina, bradyarrhythmias, uncontrolled hypertension, high-degree atrioventricular block, severe aortic stenosis, or uncontrolled hypothyroidism
Serotonin syndrome
- Coadministration of gepirone with selective serotonin reuptake inhibitors (SSRIs) or tricyclic antidepressants may cause serotonin syndrome, a potentially life-threatening condition with changes including altered mental status, hypertension, restlessness, myoclonus, hyperthermia, hyperreflexia, diaphoresis, shivering, and tremor
Drug interaction overview
CYP3A4 inhibitors
- Strong CYP3A4 inhibitor: Contraindicated
- Moderate CYP3A4 inhibitor: Reduce gepirone dose
- A strong and moderate CYP3A4 inhibitor increases gepirone exposure by ~ 5-fold and ~2.4 fold
CYP3A4 inducers
- Strong CYP3A4 inducers: Avoid coadministration
- Strong CYP3A4 inducers reduce gepirone exposure by 20- to 29-fold
MAOIs
- Coadministration with MAOIs is contraindicated; do not initiate gepirone in patient with MAOIs (eg, linezolid, IV methylene blue)
- If MAOI (eg, linezolid, IV methylene blue) is necessary in a gepirone-treated patient, discontinue gepirone before initiating a MAOI
Serotonergic drugs
- Monitor for symptoms of serotonin syndrome
- If concomitant use of gepirone with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms
- Immediately discontinue gepirone and/or concomitant serotonergic drugs if symptoms occur and initiate supportive symptomatic treatment
QT prolonging drugs
- Monitor patients with ECGs more frequently
- Drugs that prolong the QTc interval may potentiate to the QTc prolonging effects of gepirone and increase the risk of cardiac arrhythmias
Pregnancy & Lactation
Pregnancy
There are insufficient clinical data on gepirone use during pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes
There are clinical considerations regarding neonates exposed to serotonergic antidepressants during third trimester of pregnancy
Pregnancy exposure registry
- Registry monitors pregnancy outcomes in women exposed to antidepressants during pregnancy
- Encourage patients to register patients by calling the National Pregnancy Registry for Antidepressants at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/research/pregnancyregistry/antidepressants/
Animal data
- Gepirone has been shown to have adverse effects on embryofetal and postnatal development
- In rats, increased mortality during the first 4 days after birth and persistent reduction in body weight through lactation and weaning were observed at all doses and increased still births were seen with no observed adverse effect level (NOAEL) at 3 times the maximum recommended human dose (MRHD) on a mg/m2 basis
- In embryofetal development studies in rats and rabbits, decreased embryofetal growth, body weights and lengths, with accompanying skeletal variations were seen with a NOAEL at 9 and 12x the MRHD on a mg/m2 basis, respectively
Disease-associated maternal and/or embryofetal risk
- Women who discontinue antidepressants during pregnancy are more likely to experience a relapse of major depression than women who continue antidepressants
- Consider the risk of untreated depression when discontinuing or changing treatment with antidepressant medication during pregnancy and postpartum
Fetal/neonatal adverse reactions
- Neonates exposed to other serotonergic antidepressants in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Complications can arise immediately upon delivery
- Reported clinical findings include respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremors, jitteriness, irritability, and constant crying
Lactation
There are no data on the presence of gepirone in human milk, the effects on the breastfed infant, or the effects on milk production
Present in rat milk; when a drug is present in animal milk, it is likely that drug will be present in human milk
There are reports of breastfed infants exposed to other serotonergic antidepressants experiencing irritability, restlessness, excessive somnolence, decreased feeding, and weight loss
Monitor breastfeeding infants for adverse reactions (eg, irritability, restlessness, excessive somnolence, decreased feeding, weight loss)
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Serotonin (5HT)-1a agonist
Mechanism of the antidepressant effect is not fully understood
May be related to its modulation of serotonergic activity in the CNS through selective agonist activity at 5HT1A receptors
Absorption
Bioavailability: 14-17%
Steady-state achieved within 2-4 days
Effects of food
- High-fat meal: Peak plasma time reached 3 hr
- Systemic gepirone exposure and major metabolites were consistently higher under fed conditions as compared to the fasted state
- Gepirone peak plasma concentration after intake of low-fat (~ 200 calories) breakfast was 27% higher, after medium-fat (~500 calories) breakfast 55% higher and after a high-fat (~ 850 calories) breakfast 62% higher as compared to the fasted state
Distribution
Vd: 94.5 L
Protein-bound
- Gepirone: 72% and is not concentration dependent
- Metabolite: 59% (3’-OH gepirone) and 42% (1-PP)
Metabolism
Primarily metabolized by CYP3A4 to its major pharmacologically active metabolites
Both major metabolites 1-PP and 3’-OH-gepirone are present in plasma in higher concentrations than parent compound
Elimination
Half-life: 5 hr
Excretion
- Feces: 13%
- Urine: 81%
Administration
Oral Administration
Take with food
Swallow tablets whole; do not cut, crush, or chew
Storage
Store at 20-25ºC (68-77ºF); excursions permitted to 15-30ºC (59-86ºF)
Protect from high humidity and moisture
Images
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.